Evidence map›Paper›PMID 32619305›Full record

ArticleBrain pathology (Zurich, Switzerland)2021

Biology and grading of pleomorphic xanthoastrocytoma-what have we learned about it?

Rachael Vaubel, Valentina Zschernack, Quynh T Tran, Sarah Jenkins, Alissa Caron, Dragana Milosevic, James Smadbeck, George Vasmatzis, Daniela Kandels, Astrid Gnekow and 7 more

Open access · hybridAbstract read
In one paragraph

Article in Brain pathology (Zurich, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 71 citations in OpenAlex.

  1. Article
  2. Association of CDKN2A/B and MTAP deletions in adult-type diffuse gliomas.Journal of neuropathology and experimental neurology · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. PXA-like tumors: prognostic implications.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2025
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Case Report:Frontiers in oncology · 2025
    Article
  16. Article
  17. Article
  18. Paediatric low-grade glioma: the role of classical pathology in integrated diagnostic practice.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2024
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 3 countries.

Rachael VaubelDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0001-8842-5975
Valentina ZschernackInstitute of Neuropathology, DGNN Brain Tumor Reference Center, University of Bonn, Bonn, Germany.
Quynh T TranDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Sarah JenkinsDivision of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
Alissa CaronDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Dragana MilosevicDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
James SmadbeckCenter for Individualized Medicine, Mayo Clinic, Rochester, MN, USA.
George VasmatzisCenter for Individualized Medicine, Mayo Clinic, Rochester, MN, USA.
Daniela KandelsSwabian Children's Cancer Center, University Hospital Augsburg, Augsburg, Germany.
Astrid GnekowSwabian Children's Cancer Center, University Hospital Augsburg, Augsburg, Germany.
Christof KrammDivision of Pediatric Hematology and Oncology, University of Goettingen, Goettingen, Germany.
Robert JenkinsDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Benjamin R KippDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Fausto J RodriguezDivision of Neuropathology, Department of Pathology, Johns Hopkins Hospital, Baltimore, MD, USA.ORCID 0000-0001-8662-1219
Brent A OrrDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Torsten PietschInstitute of Neuropathology, DGNN Brain Tumor Reference Center, University of Bonn, Bonn, Germany.
Caterina GianniniDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0003-2757-6782
Mayo Clinic in Arizona · USMayo Clinic · USSt. Jude Children's Research Hospital · USUniversity Hospital Augsburg · DEUniversity of Bonn · DEJohns Hopkins Hospital · USUniversity of Göttingen · DE

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI AKHILESH PANDEY · 1985 to 2026
$151.3M
Deutsche Kinderkrebsstiftung (German Children Cancer Foundation) DKS 2006.03Deutsche Kinderkrebsstiftung (German Children Cancer Foundation) DKS 2009.19Deutsche Kinderkrebsstiftung (German Children Cancer Foundation) DKS 2011.01Deutsche Kinderkrebsstiftung (German Children Cancer Foundation) DKS 2014.17Mayo ClinicNCI NIH HHS P30 CA015083
6 · The paper itself

Abstract

Pleomorphic xanthoastrocytoma (PXA) is a rare astrocytoma predominantly affecting children and young adults. We performed comprehensive genomic characterization on a cohort of 67 patients with histologically defined PXA (n = 53, 79%) or anaplastic PXA (A-PXA, n = 14, 21%), including copy number analysis (ThermoFisher Oncoscan, n = 67), methylation profiling (Illumina EPIC array, n = 43) and targeted next generation sequencing (n = 32). The most frequent alterations were CDKN2A/B deletion (n = 63; 94%) and BRAF p.V600E (n = 51, 76.1%). In 7 BRAF p.V600 wild-type cases, alternative driver alterations were identified involving BRAF, RAF1 and NF1. Downstream phosphorylation of ERK kinase was uniformly present. Additional pathogenic alterations were rare, with TERT, ATRX and TP53 mutations identified in a small number of tumors, predominantly A-PXA. Methylation-based classification of 46 cases utilizing a comprehensive reference tumor allowed assignment to the PXA methylation class in 40 cases. A minority grouped with the methylation classes of ganglioglioma or pilocytic astrocytoma (n = 2), anaplastic pilocytic astrocytoma (n = 2) or control tissues (n = 2). In 9 cases, tissue was available from matched primary and recurrent tumors, including 8 with anaplastic transformation. At recurrence, two tumors acquired TERT promoter mutations and the majority demonstrated additional non-recurrent copy number alterations. Methylation class was preserved at recurrence. For 62 patients (92.5%), clinical follow-up data were available (median follow-up, 5.4 years). Overall survival was significantly different between PXA and A-PXA (5-year OS 80.8% vs. 47.6%; P = 0.0009) but not progression-free survival (5-year PFS 59.9% vs. 39.8%; P = 0.05). WHO grade remained a strong predictor of overall survival when limited to 38 cases defined as PXA by methylation-based classification. Our data confirm the importance of WHO grading in histologically and epigenetically defined PXA. Methylation-based classification may be helpful in cases with ambiguous morphology, but is largely confirmatory in PXA with well-defined morphology.

Indexed as

AdolescentAdultAgedAstrocytomaBrain NeoplasmsChildChild, PreschoolCohort StudiesDNA MethylationFemaleHumansMaleMiddle AgedNeoplasm GradingYoung Adultastrocytomagliomamethylationpleomorphic xanthoastrocytoma

Identifiers

PMID32619305
PMCPMC8018001
OpenAlexW3040295629

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.